Abstract
The correlation between tumor-infiltrating lymphocytes (TILs) and immunotherapy responses is an evolving field with significant clinical implications. Immunotherapy has revolutionized antineoplastic therapies, offering promising results for patients diagnosed with solid tumors. Integrating biomarkers, refining imaging techniques, and developing non-invasive methods may enhance personalized medicine, optimizing treatment strategies while minimizing adverse effects. In our study, we conducted a retrospective analysis to assess the practicality of utilizing the predictive value of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME) correlating the response to immunotherapy in patients with solid tumors, comprehensively navigating through currently available data. Continued research efforts and collaboration between scientists and clinicians are essential to unlock the full potential of these biomarkers and advance the field of immunotherapy in solid tumors.